A phase II trial using thalidomide for Langerhans cell histiocytosis

Pediatric Blood and Cancer

Volumn 48, Issue 1, 2007, Pages 44-49

  McClain, Kenneth L ^a,c   Kozinetz, Claudia A ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Department of Pediatrics Epidemiology Center ^*  (United States)

^c TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

Anti cytokine therapy; Langerhans cell histiocytosis; Phase II trial; Salvage therapy; Thalidomide

Indexed keywords

ASPARAGINASE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE; VINCRISTINE;

ARTICLE; BONE MARROW; BONE MARROW DEPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEPRESSION; DRUG INHIBITION; FEMALE; HIGH RISK PATIENT; HISTIOCYTOSIS X; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS; LIVER; LIVER FAILURE; LUNG; LUNG INSUFFICIENCY; MALE; MOOD DISORDER; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN; SKIN DISEASE; SLEEP DISORDER; SPLEEN; TISSUE DISTRIBUTION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; MIDDLE AGED; REMISSION INDUCTION; RISK FACTORS; THALIDOMIDE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845346464     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20578     Document Type: Article

References (33)

1. McClain KL, Hutter JJ, Cassady JR. Langerhan's cell histiocytosis. In: Cassady JR, edition Radiation therapy in pediatric oncology. New York: Springer-Verlag; 1994. pp 337-350.
2. Gadner H, Heitger A, Grois N, et al. Treatment strategy for disseminated Langerhans cell histiocyhtosis. Med Pediatr Oncol 1994;23:72-80.
3. Titgemeyer C, Grois N, Minkov M. et al. Pattern and course of single-system disease in Langerhans cell histiocytosis, data from the DAL-HX 83- and 90-study. Med Pediatr Oncol 2001;37:108-114.
4. Geissmann F. Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 2001;97:1241-1248.
5. Egeler RM, Favara BE, van Meurs M, et al. Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: Abundant expression of cytokines relevant to disease and treatment. Blood 1999;94:4195-4201.
6. Caux C, Dezutter-Dambuyant D, Schmitt D, et al. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 1992;360:258-260.
7. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-α inhibitor: Implications for clinical use. Clin Immunol Immunopath 1996;81:219-223.
8. Gnassia A, Gnassia R, Bonvalet D, et al. Histiocytose X avec 'granulome éosinophile vulvairé'. Effet spectaculaire de la thalidomide. Ann Dermatol Venereol 1987;114:1387-1389.
9. Bensaid P, Machet L, Vaillant L, et al. Langerhans-cell histiocytosis in the adult: Regressive parotid involvement following thalidomide therapy. Ann Dermatol Venereol 1992;119:281-283.
10. Misery L, Larbre B, Lyonnet S, et al. Remission of Langerhans cell histiocytosis with thalidomide treatment. Clin Exp Dermatol 1993;18:487.
11. Thomas L, Ducros B, Secchi T, et al. Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Arch Dermatol 1993;129:1261-1264.
12. Meunier L, Marck Y, Ribeyre C, et al. Adult cutaneous Langerhans cell histiocytosis: Remission with thalidomide treatment [Letter]. Br J Dermatol 1995;132:1.
13. Gerlach B, Stein A, Fischer R, et al. Langerhans cell histiocytosis in the elderly. Hautarzt 1998;49:23-30.
14. Dallafior S, Pugin P, Cerny T, et al. Successful treatment of a case of cutaneous Langerhans cell granulomatosis with 2-chlorodeoxya-denosine and thalidomide]. Hautarzt 1995;46:553-560.
15. Santillan A, Montero AJ, Kavanagh JJ, et al. Vulvar Langerhans cell histiocytosis: A case report and review of the literature. Gynecol Oncol 2003;91:241-246.
16. Padula A, Medeiros LJ, Silva EG, et al. Isolated vulvar Langerhans cell histiocytosis: A report of two cases. In J Gynecol Pathol 2004;23:278-283.
17. Sander CS, Kaatz M, Elsner P. Successful treatment of cutaneous Langerhans cell histiocytosis with thalidomide. Dermatology 2004;208:149-152.
18. Mortazavi H, Ehasani A, Namazi MR, et al. Langerhans cell histiocytosis. Dermatol Online J 2002;8:18.
19. Kolde G, Schulze P, Sterry W. Mixed response to thalidomide therapy in adults: Two cases of multisystem Langehans cell histiocytosis. Acta Derm Venereol 2002;82:384-386.
20. Claudon A, Dietemann JL, Hamman De Compte A, et al. Interest in thalidomide in cutaneo-mucous and hypothalamo-hypophyseal involvement of Langerhans cell histiocytosis. Rev Med Intern 2002;23:651-656.
21. Pouaha J, Martin S, Trechot P, et al. Thalidomide and thrombosis: Three observations. Presse Med 2001;30:1008-1009.
22. Moraes M, Russo G. Thalidomide and its dermatologic uses. Am J Med Sci 2001;321:321-326.
23. Lair G, Marie I, Cailleux N, et al. Langerhans histiocytosis in adults: Cutaneous and mucous lesion regression after treatment with thalidomide. Rev Med Int 1998;19:196-198.
24. Mauro E, Fraulini C, Rigolin GM, et al. A case of disseminated Langerhans' cell histiocytosis treated with thalidomide. Eur J Haematol 2005;74:172-174.
25. Vassallo R, Ryu JH, Colby TV, et al. Pulmonary Langerhans'-cell histiocytosis. New Engl J Med 2000;342:1969-1978.
26. Moreira AL, Sampaio EP, Smuidzina A. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 1993;177:1675-1680.
27. Sampaio EP, Sarno EN, Galilly R. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991;173:699-703.
28. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogensesis. Proc Natl Acad Sci 1994;91:4082-4085.
29. McHugh SM, Rifkin IR, Deighton J. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995;99:160-167.
30. Tseng S, Pak G, Washenik K, et al. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969-979.
31. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. New Engl J Med 1992;326:1055-1058.
32. Rovelli A, Arrigo C, Nesi F, et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant 1998;21:577-581.
33. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is wel tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-3067.